

4DryField® PH

PROVIDES HEMOSTASIS – PREVENTS ADHESIONS

Instructions for use



4DryField® PH

EXPLANATION OF SYMBOLS



Manufacturer



Manufacturing date



Use by year and month



Reference number



Batch number



Sterilization method: Radiation



Do not re-sterilize



Do not use if package is damaged



Protect from sunlight



Store dry



Do not reuse



Observe the directions for use



Attention, see instruction for use



Medical device



Applicator (content)



Box (with applicators)



CE Mark

4DryField® PH

Hemostasis – Adhesion Prevention

Intended purpose

4DryField® PH is a single-use, sterile resorbable starch-based powder for short-term use in case when hemostasis shall be achieved and/or adhesions shall be prevented. Specifically, 4DryField® PH is indicated if pressure, ligatures, or other conventional measures are not effective or impractical to control bleeding from arterioles, capillaries, or veins during surgery or surgical injury. In addition, it is also indicated to prevent the formation of post-operative adhesions following surgery or surgical injuries in peritoneal and pericardial cavities. It is used by physicians or medical professionals. It may be used in adults, children and neonates. It is intended to be used under sterile conditions during surgeries in healthcare facility settings, such as hospitals and specialized medical practices. It may be used in combination with the laparoscopic applicator 4DFLap™ and sterile solutions as well.

Description

4DryField® PH consists of hydrophilic, microporous particles produced from processed plant starch using the special SAFE™ technology. Due to its fluidity, 4DryField® PH can be applied easily and safely during surgical procedures or in case of surgical injuries.

4DryField® PH does not contain any components of human and/or animal origin. Due to its excellent tolerability, up to 1g of 4DryField® PH can be administered per 1 kg body weight^[1, 2]. 4DryField® PH is a fine, dry, biocompatible and pyrogen-free powder, which is usually resorbed within seven days [1]. 4DryField® PH is mainly degraded by amylase and glucoamylase. Duration of degradation depends upon several factors, including application technique, amount and where applied.

Performance characteristics of the product

For hemostasis:

Due to its molecular structure, 4DryField® PH extracts water from the blood and, therefore, the cellular blood components (e.g., erythrocytes, platelets) as well as blood proteins (e.g., fibrinogen, thrombin) are concentrated. As a result, cellular hemostasis and the coagulation cascade are accelerated and a stable clot is formed from 4DryField® PH and blood.

The conglomerate of 4DryField® PH and blood seals the bleeding source and stops any further bleeding. Disadvantages of a dilutional coagulopathy can be compensated by the effect of 4DryField® PH [2].

For adhesion prevention:

Due to the special molecular structure of 4DryField® PH, the hydrophilic, microporous particles form a gel through absorption of liquid. To prevent post-operative adhesions, 4DryField® PH is transformed into a gel with sterile solution.

This gel acts as a temporary, mechanical barrier separating traumatized mesothelial (or mesothelial-like) surfaces (risk zones for the formation of adhesions) during the post-operative healing phase [3-5].

Medical Indications

For hemostasis:

4DryField® PH is indicated if pressure, ligatures, or other conventional measures are not effective or impractical to control bleeding from arterioles, capillaries, or veins during surgery or surgical injury.

For adhesion prevention:

4DryField® PH is also indicated to prevent the formation of post-operative adhesions following surgery or surgical injuries in peritoneal and pericardial cavities.

Patient population

4DryField® PH can be used in adults, children and neonates:

- In the presence of limited available data supporting the use of 4DryField® PH on sensitive population groups such children and neonates this product should be used with caution and following a clinician's recommendation.
- In the absence of available data supporting the use of 4DryField® PH on sensitive population groups such as pregnant or nursing women, and in the absence of data to the contrary, on these population groups this product should be used with caution and following a clinician's recommendation.

Intended environment

The device is intended to be used under sterile conditions during surgeries in healthcare facility settings, such as hospitals and specialized medical practices.

Intended user

The device is intended to be used by physicians or medical professionals.

Application

4DryField® PH is intended for use by physicians and medical/technical professionals only. The following instructions for use provide an overview of the recommended use of 4DryField® PH. The procedures described do not represent all possible clinical procedures. This Instructions for Use is therefore not a substitute for product training, medical experience and judgment in the treatment of certain clinical situations.

Preparation:

1. Before using 4DryField® PH, check the integrity of the sterile barrier system. If the sterile barrier system is damaged, do not use 4DryField® PH. The local distributor must be contacted in this case.
2. Remove the bellows bottle from the sterile barrier system.
3. Remove the cap of the bellows bottle using a slight bending and rotating movement. 4DryField® PH is ready to use.

Clinical application for hemostasis:

1. Best possible cleaning and drying (e.g. suction, standard gauze) of the bleeding surfaces (see Figure 1). Excess blood should be removed. 4DryField® PH has its best effect when applied as directly as possible to the source of the bleeding.
2. Apply 4DryField® PH until complete **hemostasis** is achieved (see Figure 2). The entire wound area should be covered by 4DryField® PH. Avoid contact of the tip of the bellows bottle with blood, moisture, tissue or organs if possible to prevent clogging of the bellows bottle.
3. Whenever necessary, apply appropriate, even pressure to the bleeding surface (e.g. via standard gauze) until **hemostasis** is achieved (see Figure 3). The duration and strength of the pressure depend on the treated organ, the strength of the bleeding and the size of the wound area. Before removing the

1. Starch-based Agent Functionally Engineered

2. Tested in animals

standard gauze, soak it with sterile solution to prevent it from sticking to the formed clot (if necessary) (see Figure 4). Pressure may not be necessary if bleeding persists.

4. If bleeding persists, remove the excess 4DryField® PH powder, then repeat the application of 4DryField® PH.

5. 4DryField® PH swells to its maximum volume within minutes after contact with blood or other fluids. Excess 4DryField® PH powder should be removed or soaked with sterile solution after achieving hemostasis (see Figure 5).



Fig. 1: Clean and dry the bleeding surfaces.



Fig. 2: Apply 4DryField® PH until hemostasis is achieved.



Fig. 3: Whenever necessary, apply pressure to the bleeding.



Fig. 4: Before removing a gauze, soak with sterile solution.



Fig. 5: Soak excess 4DryField® PH powder with sterile solution.

If 4DryField® PH is also to be used for **adhesion prevention**, 4DryField® PH is applied as powder using one of the following instructions for use either on traumatized, mesothelial (or mesothelial-like) surfaces (risk zones for the formation of adhesion) and transformed into a gel that is as free of blood as possible, or first converted into a gel and then applied.

If the gel is locally penetrated by blood, the effect of 4DryField® PH for **adhesion prevention** may be reduced there.

Clinical application for adhesion prevention:

An important prerequisite for successful **adhesion prevention** is effective **hemostasis**. In many cases, 4DryField® PH can be used for this purpose as described in the above instructions for use.

For **adhesion prevention**, 4DryField® PH can be used according to one of the following two instructions for use (depending on the clinical situation) on mesothelial (or mesothelial-like)-covered cavities (abdominal cavity, pericardium).

1. **Adhesion prevention** with 4DryField® PH as in-situ transform-gel:

1.1. Best possible cleaning (e.g. suction, standard gauze) and rinsing of the surfaces to be treated.

1.2. Apply 4DryField® PH in sufficient quantity until the entire defect is completely covered by 4DryField® PH (see Figure 6). This also applies to large wound areas (e.g. pelvic exenteration, large peritoneal, pericardial defects). 4DryField® PH that is applied to non-traumatized mesothelial (or mesothelial-like) surfaces, has no negative effects [1]. Care should be taken to ensure that the top of the powder layer is as free of blood as possible. Avoid contact of the tip of the bellows bottle with blood, moisture, tissue or organs if possible, to prevent clogging of the bellows bottle.

1.3. After applying 4DryField® PH as a powder, it is soaked in sterile solution (see Figure 7) until no white 4DryField® PH powder is visible anymore and a gel completely covers the surfaces to be treated (see Figure 8). When closing a body cavity, make sure that there are no compression effects caused by 4DryField® PH gel.



Fig. 6: Administer 4DryField® PH until the entire defect is covered.



Fig. 7: Soak the powder in sterile solution.



Fig. 8: ... until no white 4DryField® PH powder is visible and a gel covers the surface.

2. **Adhesion prevention** with 4DryField® PH as extracorporeal premixed gel:

2.1. Add 4DryField® PH powder in a suitable, clean, sterile vessel (e.g. mix or kidney dish) (see Figure 9). Depending upon the required viscosity, add approximately 10 ml³ of sterile solution per 1 g of powder [6-8] (see Figure 10). Mix 4DryField® PH and sterile solution to a homogeneous gel using an appropriate instrument (see Figure 11). Always follow the Instructions for Use for the respective vessels and instruments used.

2.2. Best possible cleaning (e.g. suction, standard gauze) and rinsing of the surfaces to be treated.

2.3. Then transfer the gel into a syringe of a suitable volume (see Figure 12) and apply it to the surfaces to be treated for **adhesion prevention** (see Figure 13). Always follow the instructions for use for the respective syringe.

OR

Apply the gel from the mixing vessel directly to the surfaces to be treated for **adhesion prevention** (see Figure 14).



Fig. 9: Place 4DryField® PH as powder into a suitable vessel.



Fig. 10: Depending upon the required viscosity, add sterile solution to the powder.



Fig. 11: Mix 4DryField® PH and sterile solution into a homogeneous gel.



Fig. 12: Transfer gel into a syringe with suitable volume.



Fig. 13: Apply the gel from the syringe to the surface to be treated.



Fig. 14: Apply the gel directly from the mixing vessel.

If 4DryField® PH is used in conjunction with extracorporeal cardiopulmonary circulation (heart-lung machine) or an autologous **cell saving** (blood processing) system, use 40 µm filters and/or **cell washing**.

If 4DryField® PH is to be applied to difficult-to-access, indicated areas using 4DFlap™ applicators, or used endoscopically or laparoscopically (minimally invasive surgery), always follow the instructions for use for the specific applicators used. The following applicators are recommended for use with 4DryField® PH:

- LA0014-EU: 4DFlap™ applicator with 14 cm long application cannula
- LA0038-EU: 4DFlap™ applicator with 38 cm long application cannula

It is not recommended to use other application aids.

-
- 3. Mixtures between 8 and 14 ml of isotonic saline solution per 1 g of 4DryField® PH powder have been clinically investigated [6-8]
 - 4. For a firm gel, add 8 to 10 ml, for a more fluid gel, 10 to 14 ml of isotonic saline solution per 1 g of powder.

Instructions for use for endoscopic or laparoscopic surgery

The above instructions for use for the treatment of the defined indications **hemostasis** and/or **adhesion prevention** must be followed. In addition, the following steps must be performed:

1. Necessary trocars must be installed correctly before using 4DryField® PH and 4DFlap™ applicator [23, 24]. Always follow the instructions for use for the respective trocar used to ensure proper application of 4DryField® PH to indicated areas.

Keep an eye on the tip of the 4DFlap™ applicator at all times during application to minimize the risk of accidental contact of 4DFlap™ with blood, moisture, tissue or organs and the possibility of clogging the tip of the applicator.

2. If the 4DFlap™ applicator gets clogged during use, replace it with a new 4DFlap™ applicator.

3. After use, carefully remove the 4DFlap™ applicator from the trocar.

See the 4DFlap™ instructions for use for complete information on 4DFlap™ when administering 4DryField® PH.



Fig. 15: LA0014-EU with a 14 cm long flexible application cannula extends the reach of 4DryField® PH.



Fig. 16: LA0038-EU with a 38 cm long flexible application cannula enables the application of 4DryField® PH through a trocar.

Product Training

For optimal application of 4DryField® PH, participation in product trainings or similar by the manufacturer's or distributor's product specialists is recommended prior to first use.

Contraindications

DryField® PH must not be administered intravascularly, as this may cause embolization and in extreme cases death!

4DryField® PH is contraindicated for known hypersensitivity to starch or starch-containing substances.

Avoid application of 4DryField® PH into the bladder and ureter, as 4DryField® PH binds fluid and subsequently swells.

4DryField® PH is not indicated for adhesion prevention in the pleural cavity as use in pleural cavity has not been systematically investigated.

4DryField® PH is not indicated for the primary treatment of coagulation disorders.

4DryField® PH is contraindicated in the event of complete failure of one or more coagulation factors.

4DryField® PH is not indicated for ophthalmological procedures.

Warnings

WARNING

The safety and effectiveness of 4DryField® PH in combination with other medical devices for hemostasis and/or for adhesion prevention or adhesive agents have not been systematically investigated.

4DryField® PH has not been systematically investigated in **neurosurgery** applied in the cranial cavity, it must be considered that 4DryField® PH swells due to the absorption of fluid.

Special care should be taken when using 4DryField® PH in conjunction with **cardiopulmonary circulation** or autologous **cell-saving** systems. The penetration of particles is prevented by the

use of 40 µm filters and **cell washing**. It is essential to follow the filter manufacturer's instructions for correct use.

4DryField® PH does not replace a careful surgical technique of hemostasis with ligatures or other conventional measures. When 4DryField® PH is used in the area around the osseous **foramina of the skull**, in the area of the **spinal column**, the **spinal cord** or in the area of **nerves** where nerve compression may occur (e.g. *Nervus opticus*, *Chiasma opticum*), remove excess 4DryField® PH. In particular, any remaining white 4DryField® PH should be removed. Removing the excess reduces the likelihood of disturbances of normal functions or the development of compression necrosis induced by the pressure of swelled 4DryField® PH.

When 4DryField® PH is used for hemostasis and/or adhesion prevention in the area of the right atrium of the **heart**, it is necessary to ensure that no compression can occur.

When 4DryField® PH is applied for hemostasis within the **respiratory tract**, remove any white 4DryField® PH powder after hemostasis is achieved and superficially soak the remaining 4DryField® PH with sterile solution. Removal and soaking strongly reduces the likelihood of 4DryField® PH blocking the airway.

4DryField® PH can theoretically mask tissue or vascular perforations due to its physical properties. It is therefore necessary to ensure that there is no persistent bleeding before the end of the operation.

If bleeding persists, remove the excess powder of 4DryField® PH, then repeat the application of 4DryField® PH.

After a surgery on the **heart**, it is recommended not to deviate from standard practice. Mediastinal chest drains including pericardial drains are inserted as standard postoperative procedure to assist the clearance of blood from the pericardial space.

4DryField® PH is a single-use product and must not be reused.

4DryField® PH is not to be used after the expiry date as indicated on the sterile barrier system and on the packaging.

Precautions

CAUTION

In the presence of limited available data supporting the use of 4DryField® PH on sensitive population groups such children and neonates this product should be used with caution and following a clinician's recommendation.

In the absence of available data supporting the use of 4DryField® PH on sensitive population groups such as pregnant or nursing women, and in the absence of data to the contrary, on these population groups this product should be used with caution and following a clinician's recommendation.

When used in **neurosurgery**, 4DryField® PH is not suitable for treating CSF leakage, as cerebrospinal fluid (CSF) is not a coagulable fluid.

When using 4DryField® PH on **bone surfaces** where prosthetic material is to be attached by means of adhesives or bone cement, any excess particles must be completely rinsed from the bone surfaces to be treated.

4DryField® PH should not be used on infected tissue. If there are signs of an infection or abscess in an area where 4DryField® PH has been applied, an additional surgery to insert a drainage may be necessary.

In **neonates** up to ten months of age, amylase activity may be reduced, which may reduce the degradation rate of products such as 4DryField® PH. No problem caused by this possible effect has been reported to date.

Hematoma may be formed after hemostasis. Drainage due to the use of 4DryField® PH for hemostasis is recommended, although clinical data show that 4DryField® PH can significantly reduce the formation of postoperative hematomas [9].

4DryField® PH can only develop its hemostatic effect in a dry state. Contact with saline solution or other fluids (e.g. antibiotics or Ringer's solution, cerebrospinal fluid, urine) can reduce the hemostatic potential.

In **urological procedures**, 4DryField® PH should not enter the renal pelvis to exclude the potential for kidney stone formation.

For **diabetics**, it should be noted that 1 g of completely degraded 4DryField® PH corresponds to approximately 4 mmol glucose and would result in an increase of 0.8 mmol glucose per liter in 5 L of blood (about the average value for adults). However, since degradation takes place over days, the real values are much lower and consequently no problematic increase in glucose is to be expected even with unusually high doses.

Abdominal discomfort after surgery is a relatively common symptom, which can have a variety of causes. A causal relationship between treatment with 4DryField® PH and the onset of symptoms has not been examined.

Post-operative adhesions may occur despite the use of 4DryField® PH. Possible causes include insufficient hemostasis, a blood-infused gel, or improper use.

NOTICE

4DryField® PH is only intended for use by physicians and medical/technical professionals.

In the case of active bleedings (e.g. in the **spinal canal**), other measures may be necessary to achieve hemostasis.

4DryField® PH should not be used to control **postpartum bleedings** or **menorrhagia**.

Polysaccharides such as 4DryField® PH may interfere with the adhesion of acrylic-based adhesives.

In rare cases, 4DryField® PH degradation may be delayed or severely delayed. This can occur when large amounts of powder remain in the body without subsequent transformation into a gel. Abscesses, inflammatory reactions, encapsulation or similar consequences of delayed degradation have not been reported to date. For this reason, care should be taken to ensure that all excess powder is rinsed with sterile solution at the end of the treatment.

Side Effects

In rare cases, a selective increase of the **C-reactive protein (CRP)** concentration was reported in the first days after 4DryField® PH administration, which spontaneously returned to normal levels within a few days [25]. This increase, which may be induced by starch degradation, is not usually associated with an increase in other inflammatory parameters (e.g. body temperature, leucocytes). If other inflammatory parameters are increased in addition to CRP concentration, an infection that requires treatment may be present, regardless of 4DryField® PH. In this case, appropriate measures must be taken.

Experimental Data

Due to its excellent tolerability, up to 1 g of 4DryField® PH can be administered per 1 kg body weight [1].

In an *in vitro* study, no significantly better growth of *Escherichia coli* in medium with 4DryField® PH compared to a control group (without 4DryField® PH) was demonstrated. This indicates that 4DryField® PH does not promote wound infection [10].

Furthermore, it was shown that the insertion of hernia nets

combined with 4DryField® PH gel can significantly reduce adhesions [11, 12].

Clinical Data

4DryField® PH for hemostasis, especially for diffuse bleedings, has been shown to be safe and effective in clinical studies in general surgery [13, 26], gynecology [6, 14-18], plastic surgery [19], trauma surgery [9] and urology [20].

Safety and high efficacy concerning adhesion prevention were demonstrated in clinical studies including second-look surgeries in general surgery [7, 8], cardiac surgery [21] and gynecology [6, 14, 15, 17, 18, 22]. A significant reduction in the severity and extent of adhesions was confirmed [8, 17, 21, 22]. In addition, it has been shown that 4DryField® PH can be used safely and effectively for adhesion prevention, both as a powder with subsequent soaking with saline solution and in the form of an extracorporeally premixed gel in different viscosities [6].

In addition, the excellent tolerability was confirmed in an adhesion prevention study in pediatric heart surgery. Up to 2 g 4DryField® PH was used as a gel per 1 kg body weight without any degradation or tolerability problems [21].

Clinical studies in general surgery [13] and urology [20] showed that 4DryField® PH was effective in lymphostasis and in the treatment of seromas. In addition, 4DryField® PH reduced postoperative lymphocele and hematoma formation [9, 20].

Dosage forms

4DryField® PH can be supplied in 1 g, 3 g, 5 g and 9 g bellows bottles:

SK0001-EU: 4DryField® PH with 1 g filling quantity
SK0003-EU: 4DryField® PH with 3 g filling quantity
SK0005-EU: 4DryField® PH with 5 g filling quantity
SK0009-EU: 4DryField® PH with 9 g filling quantity

SK0001-AS: 4DryField® PH with 1 g filling quantity
SK0003-AS: 4DryField® PH with 3 g filling quantity
SK0005-AS: 4DryField® PH with 5 g filling quantity
SK0009-AS: 4DryField® PH with 9 g filling quantity

Depending on the registration not all variants (-EU/ -AS) are available in every country.

Storage

4DryField® PH should be stored at room temperature, protected from prolonged exposure to direct sunlight. There are no other storage restrictions known beyond the conditions of normal hospital storage.

If stored properly, this product will remain fully ready for use for 5 years.

After Opening

Once the 4DryField® PH packaging has been opened, the sterile barrier is broken and there is a risk of contamination. It is recommended to use 4DryField® PH immediately after opening. Used and unused parts must be disposed of.

Note

All incidents in connection with 4DryField® PH must be reported to PlantTec Medical GmbH and the competent authority of the country in which the user and/or patient is established:

Tel.: +49 (0) 4131 394 23-60
Fax: +49 (0) 4131 394 23-8887
Email: vigilance@planttec-medical.de

Disposal

Disposal of 4DryField® PH should be made in accordance with the applicable legal requirements and local regulations for the disposal of medical devices.

1. Poehnert, D., et al. "Evaluation of the biological tolerability of the starch-based medical device 4DryField® PH in vitro and in vivo a rat model." *J Biomater Appl* 30, no. 4 (2015): 463-471.
2. Sieg, L., et al. "Effects of microporous polysaccharide powder in a model of dilution on viscoelastic characteristics of clot formation: An in-vitro study." *ARC J Anesthesiol* 2, no. 4 (2017): 10-17.
3. Poehnert, D., et al. "Evaluation of 4DryField® PH as adhesion prevention barrier tested in an optimized adhesion model in rats." *Eur Surg Res* 55, no. 4 (2015): 341-351.
4. Poehnert, D., et al. "Evaluation of the effectiveness of peritoneal adhesion prevention devices in a rat model." *Int J Med Sci* 13, no. 7 (2016): 524-532.
5. Poehnert, D., et al. "Comparison of adhesion prevention capabilities of the modified starch powder-based medical devices 4DryField® PH and Arista® AH in the optimized peritoneal adhesion model." *Int J Med Sci* 16, no. 10 (2019): 1350-1355.
6. Korell, M., et al. "Use of modified polysaccharide 4DryField® PH for adhesion prevention and hemostasis in gynecological surgery: A two-center observational study by second-look laparoscopy." *BioMed Res Int*, 3029264 (2016): 1-9.
7. Blumhardt, G., et al. "Effect of 4DryField® PH, a novel adhesion barrier, on recurrence of intestinal adhesions after extensive visceral adhesiolysis." *Case Rep Surg*, 9628742 (2018): 1-6.
8. Ahmad, M., et al. "Significant adhesion reduction with 4DryField® PH after release of adhesive small bowel obstruction." *Surg J* 5, no. 1 (2019): e28-e34.
9. Riebau, C., et al. „Reduktion des postoperativen Blutverlustes durch lokale Applikation von 4DryField® PH nach Duodokopfprothesenimplantation bei medialer Schenkelhalsfraktur.“ *Deutscher Kongress für Orthopädie und Unfallchirurgie*, Deutsche Gesellschaft für Orthopädie und Unfallchirurgie e. V., Berlin 2018.
10. Internal test report: "PX24-0001X-0001" PlantTec Medical GmbH, 2025.
11. Winny, M., et al. "Treatment of de-peritonealized intestine with 4DryField® PH prevents adhesions between non-resorbable intra-peritoneal hernia mesh and bowel." *Am J Transl Res* 8, no. 12 (2016): 5706-5714.
12. Winny, M., et al. "Adhesion prevention efficacy of composite meshes Parietex®, Proceed®, and 4DryField® PH covered polypropylene meshes in an IPOM rat model." *Int J Med Sci* 13, no. 12 (2016): 936-941.
13. Kuthe, A. "Successful treatment of a chronic abdominal wall seroma with the polysaccharide 4DryField® PH: A case report." *Int J Surg Case Rep* 27, no. 1 (2016): 48-50.
14. Korell, M. "Combined hemostasis and adhesion prevention with the novel agent 4DryField® PH: Initial observations." *Surg Sci* 5, no. 1 (2014): 533539.
15. Ziegler, N., et al. "Uterine perforation following a fractional curettage successfully treated with the modified polysaccharide 4DryField® PH: A case report." *J Med Case Rep* 10, no. 243 (2016): 15.
16. Watrowski, R. "Unifying local hemostasis and adhesion prevention during gynaecologic laparoscopies: Experience with a novel, plant-based agent." *J Obstet Gynaecol* 40, no. 4 (2020): 586-588.
17. Ziegler, N., et al. "Reduction of adhesion formation after gynaecological adhesiolysis surgery with 4DryField PH – a retrospective, controlled study with second look laparoscopies." *J Obstet Gynaecol* 304(4) 2021: 951-955.
18. Torres-de la Roche, L. A., et al. "A new approach to avoid ovarian failure as well function-impairing adhesion formation in endometrioma infertility surgery." *Arch Gynecol Obstet* 301, no. 5 (2020): 1113-1115.
19. Rudolph, M., et al. "Lymphostasis and hemostasis in body-contouring surgery using a polysaccharide-based hemostat (4DryField® PH)." *Plast Reconstr Surg Glob Open* 7, no. 3 (2019): e21-28.
20. Karsch, J. J., et al. "Evaluation of lymphorrhea and incidence of lymphoceles: 4DryField® PH in radical retropubic prostatectomy." *Adv Urol*, 2367432 (2016): 17.
21. Cesnjevar, R. "Study Report: Retrospective analysis of prophylaxis of pericardial and pleural adhesions in pediatric heart surgery with and without application of the medical device 4DryField® PH." University Hospital Erlangen, Department of Pediatric Cardiac Surgery, 2020
22. Krämer, B., et al. „Adhesion prevention after endometriosis surgery Results of a randomized, controlled clinical trial with second-look laparoscopy“ *Langenbeck's Arch Surg* 406(6) 2021: 2133-2143.
23. Performance Testing: Kompatibilität von 4DFLap™ mit Spritzen mit Katheteraufsatz, PlantTec Medical GmbH, 2022
24. Performance Testing: Kompatibilität von 4DFLap™ mit 5 mm Trokaren, PlantTec Medical GmbH, 2022.
25. Ziegler, N. et al. "Changed inflammatory markers after application of 4DryField PH for adhesion prevention in gynecological surgery." *Arch Gynecol Obstet*, 304(4) 2021: 951-955
26. Wu, X., "Study report: A clinical study to evaluate the safety and efficacy of 4DryField® PH in assisting in hemostasis of bleeding wound in general surgery" The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou



4DryField® PH

PROVIDES HEMOSTASIS – PREVENTS ADHESIONS

SIMPLE

Ready to use

Easy application

No special storage conditions

Simple and fast laparoscopic application with the **4DFlap™ applicator**

SAFE

Purely plant-based

- No human or animal components
- No risk of disease transmission

Excellent tolerability¹

- Not cytotoxic
- Up to 1 g/kg body weight is well tolerated
- Does not enhance viability of tumor cells
- Promotes recovery

Free of pyrogens²

Resorption within 7 days¹

No documentation requirement as per German transfusion law

EFFECTIVE

Immediate hemostasis³⁻¹⁰

Highly effective adhesion prevention⁵⁻¹⁷

1 g of 4DryField® PH is enough for ~25 cm²

CE 0482



PlantTec Medical

MEDICAL SOLUTIONS INSPIRED BY NATURE

PlantTec Medical GmbH

Dorette-von-Stern-Str. 10 Tel.: +49 4131 394 23 60

21337 Lüneburg

Germany

Fax: +49 4131 394 23 8887

eMail: info@planttec-medical.de

For further information and videos, please visit

www.planttec-medical.de

References:

1. Poehnert et al. 2015 J Biomater Appl, 2. Bioserv 2016 Study Report, 3. Hanke et al. 2011 ASA Meeting, 4. Sieg et al. 2017 ARC J Anesthesiol, 5. Korell 2014 Surgical Science, 6. Korell et al. 2016 Biomed Res Int, 7. Poehnert et al. 2015 Eur Surg Res, 8. Ziegler et al. 2016 J Med Case Rep, 9. Watrowski 2019 J Obstet Gynaecol, 10. Ziegler & de Wilde 2019 EEC, 11. Winny et al. 2016 Am J Transl Res, 12. Winny et al. 2016 Int J Med Sci, 13. Blumhardt et al. 2018 Case Rep Surg, 14. Ahmad & Crescenti 2019 Surg J, 15. Poehnert et al. 2019 Int J Med Sci, 16. Krämer et al. 2019 EEC, 17. Torres-de la Roche et al. 2020 Arch Gynecol Obstet